4-(6,7-Dimethoxy-4-quinazolinyl)-N-[4-(3-ethylthioureido)phenyl]-1-piperazinecarboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(6,7-Dimethoxy-4-quinazolinyl)-N-[4-(3-ethylthioureido)phenyl]-1-piperazinecarboxamide
• 英文别名: 4-(6,7-dimethoxyquinazolin-4-yl)-N-[4-(ethylcarbamothioylamino)phenyl]piperazine-1-carboxamide
• 化学式: C₂₄H₂₉N₇O₃S
• 分子量: 495.605
• InChiKey: RXIJVFJJHZPTOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  136
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-(4-aminophenyl)-4-(6,7-dimethoxy-4-quinazolinyl)-1-piperazinecarboxamide 、 异硫氰酸乙酯 以 N-甲基乙酰胺 为溶剂， 以33%的产率得到4-(6,7-Dimethoxy-4-quinazolinyl)-N-[4-(3-ethylthioureido)phenyl]-1-piperazinecarboxamide
  参考文献：
  名称：

  US6169088

  摘要：

  公开号：

文献信息

• Nitrogen-containing heterocyclic compounds
  申请人：——

  公开号：US20020068734A1

  公开（公告）日：2002-06-06

  The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering and thus are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. The compounds are represented by general formula (I): 1 wherein V represents an oxygen atom or a sulfur atom; W represents 1,4-piperazinediyl or 1,4-homopiperazinediyl in which carbons on the ring may be substituted by unsubstituted alkyl groups; X represents a nitrogen atom or C-R 9 ; Y represents a nitrogen atom or C-R 8 ; Z represents a nitrogen atom or C-R 7 (provided that at least one of X, Y and Z represents a nitrogen atom); R 1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R 2 represents a substituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R 3 , R 4 , R 5 and R 6 , which may be the same or different, each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a nitro group, a cyano group, OR 12 , —NR 15 R 16 , etc.; R 7 represents a halogen atom, etc.; R 8 has the same significance as R 7 , and R 9 represents a hydrogen atom or —COR 41 .

  本发明提供了含氮杂环化合物及其药学上可接受的盐，其抑制PDGF受体的磷酸化，以阻碍异常细胞生长和细胞游走，因此可用于预防或治疗细胞增殖性疾病，如动脉硬化、血管再狭窄、癌症和肾小球硬化。所述化合物由通式（I）表示：其中V表示氧原子或硫原子；W表示1,4-哌嗪基或1,4-同源哌嗪基，其中环上的碳可以被未取代的烷基取代；X表示氮原子或C-R9；Y表示氮原子或C-R8；Z表示氮原子或C-R7（前提是X、Y和Z中至少有一个表示氮原子）；R1表示氢原子、取代或未取代的烷基、取代或未取代的脂环烷基等；R2表示取代的烷基、取代或未取代的脂环烷基等；R3、R4、R5和R6，可以相同也可以不同，每个表示氢原子、卤素原子、取代或未取代的烷基、硝基、氰基、OR12、—NR15R16等；R7表示卤素原子等；R8具有与R7相同的意义，且R9表示氢原子或—COR41。
• 1,3 diazines with platelet-derived growth factor receptor inhibitory activity
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US06207667B1

  公开（公告）日：2001-03-27

  1,3 Diazines according to formula (I): and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering. The compounds may be used to treat or prevent cell-proliferative disorders such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

  根据公式（I）的1,3二氮杂环化合物及其药学上可接受的盐抑制血小板源性生长因子受体的磷酸化，从而阻碍异常细胞生长和细胞游走。这些化合物可用于治疗或预防细胞增殖性疾病，如动脉硬化、血管再狭窄、癌症和肾小球硬化。
• NITROGENOUS HETEROCYCLIC COMPOUNDS
  申请人：KYOWA HAKKO KOGYO KABUSHIKI KAISHA

  公开号：EP0882717A1

  公开（公告）日：1998-12-09

  The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering and thus are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. The compounds are represented by general formula (I): wherein V represents an oxygen atom or a sulfur atom; W represents 1,4-piperazinediyl or 1,4-homopiperazinediyl in which carbons on the ring may be substituted by unsubstituted alkyl groups; X represents a nitrogen atom or C-R9; Y represents a nitrogen atom or C-R8; Z represents a nitrogen atom or C-R7 (provided that at least one of X, Y and Z represents a nitrogen atom); R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R2 represents a substituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R3, R4, R5 and R6, which may be the same or different, each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a nitro group, a cyano group, - OR12, -NR15R16, etc.; R7 represents a halogen atom, etc.; R8 has the same significance as R7, and R9 represents a hydrogen atom or -COR41.

  本发明提供了含氮杂环化合物及其药学上可接受的盐类，它们能抑制 PDGF 受体的磷酸化，从而阻碍细胞的异常生长和游走，因此可用于预防或治疗细胞增殖性疾病，如动脉硬化、血管再阻塞、癌症和肾小球硬化症。这些化合物由通式 (I) 表示： 其中 V 代表氧原子或硫原子； W 代表 1,4-哌嗪二基或 1,4-高哌嗪二基，其中环上的碳可被未取代的烷基取代； X 代表氮原子或 C-R9； Y 代表氮原子或 C-R8 Z 代表氮原子或 C-R7（条件是 X、Y 和 Z 中至少有一个代表氮原子）； R1 代表氢原子、取代或未取代的烷基、取代或未取代的脂环烷基等； R2 代表取代的烷基、取代或未取代的脂环烷基等； R3、R4、R5 和 R6 可以相同或不同，各自代表氢原子、卤素原子、取代或未取代的烷基、硝基、氰基、- OR12、-NR15R16 等； R7 代表卤素原子等； R8 与 R7 意义相同，以及 R9 代表氢原子或-COR41。
• US6169088B1
  申请人：——

  公开号：US6169088B1

  公开（公告）日：2001-01-02
• US6207667B1
  申请人：——

  公开号：US6207667B1

  公开（公告）日：2001-03-27